Skip to content

A clinical trial evaluating of effect of Descurainia sophia (L.) on clinical symptoms of adult patients with functional constipation

A clinical trial evaluating of effect of Descurainia sophia (L.) on clinical symptoms of adult patients with functional constipation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016030515408N2
Enrollment
35
Registered
2016-03-29
Start date
2014-12-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relationship of Descurainia sophia L. with functional constipation in adults.

Interventions

Intervention: A spoonful of dry seeds of Descurainia sophia L. and a spoonful of sugar in a cup of boiling water are mixed and taken at fasting once a day. If the properties of defecation do not sat
Treatment - Drugs

Sponsors

School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center, Shahid Be
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age: 70-20 years at the time of screening; Ability to participate in the study and there is no obvious behavioral disorders, speech and language diaeres; No major abdominal surgery; Lack of self and family history of thyroid disease; Colon cancer screening in people over 50 years; Lack of warning signs (rectal bleeding and weight loss and anemia); No underlying disease affecting constipation (Parkinson, Multiple sclerosis, stroke, hypothyroidism, cancer); Lack of pregnancy or lactation; Speaking ins; Avoiding the use of antibiotics in the past 5 weeks; Not taking medications causing constipation; No addiction; Complete the consent form; Having normal routine tests, including complete blood count, fecal occult blood test, alkaline phosphatase and TSH test, liver enzymes and Cr; No previous sensitivities to herbal medicines; Absence of severe cardiovascular disease, especially functional class 3 & 4 of chronic heart failure; Lack of proven malignancy; Absence of liver disease (esophageal varices and bleeding, encephalopathy, ascites); Absence of symptomatic gallstone disease (in history); Absence of severe kidney disease (creatinine more than 3 mg / dl); Having the criteria for functional constipation ROMIII. Main exclusion criteria: Lack of durability of the above conditions; Unwillingness to continue participation in the study; Drug side effects or other threatening events.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The proportion of patients reaching three or more spontanouse complete bowel movement/week. Timepoint: At the begining, before the intervention and 4 weeks after, at the end of study. Method of measurement: By interviews with patients and asking them.

Secondary

MeasureTime frame
The number of laxatives used. Timepoint: At the begining, before the intervention and 4 weeks after, at the end of study. Method of measurement: By interviews with the patients and asking them.;The score of a check list of Patient Assessment of Constipation Symptoms (PAC-SYM) items. Timepoint: At the begining, before the intervention and 4 weeks after, at the end of study. Method of measurement: By interviews with the patients and asking them.;The type of stool according to Bristol chart. Timepoint: At the begining, before the intervention and 4 weeks after, at the end of study. Method of measurement: By interviews with the patients and asking them.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Anahita Ghourchian

School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center, Shahid Behe

dr.anahitaghourchian@sbmu.ac.ir ; anahitaghourchian@gmail.com+98 21 8877 3525

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026